The earnings beat and raised EPS guidance are positive, but the revenue guidance cut signals a slower growth trajectory for the core business. Traders should watch for execution on the Biotronik integration and the pace of share repurchases. The FDA approval of EZPLAZ provides a new long-term catalyst, but near-term focus will be on whether the company can stabilize organic growth trends.
Price Chart
Executive Summary
Teleflex reported Q2 2026 adjusted EPS of $1.76, a 37.4% beat vs the $1.28 consensus, driven by strong Vascular and Surgical growth and aggressive capital return. However, the company reduced its full-year pro forma adjusted constant currency revenue growth guidance to 3.5%-4.5% (from 4.5%-5.5%) due to slower-than-expected integration of the acquired Biotronik Vascular Intervention business, creating a mixed picture of earnings upside against a top-line growth deceleration.
Key Financial Metrics
Key Facts
- Q2 2026 adjusted EPS of $1.76 beat consensus of $1.28 by 37.4%
- Q2 2026 revenue of $570.3M beat consensus of $559.6M by 1.9%
- Full-year pro forma adjusted constant currency revenue growth guidance reduced to 3.5%-4.5% from 4.5%-5.5%
- Full-year adjusted EPS guidance raised to $6.90-$7.20 from $6.25-$6.55
- Completed $1.5B OEM divestiture; deployed $250M for share repurchases in Q2 and announced a $250M accelerated share repurchase
- Paid off $700M Term Loan A-2 and refinanced credit facilities
- Received FDA BLA approval for EZPLAZ Freeze Dried Plasma
- Integration of Biotronik Vascular Intervention business taking longer than expected, impacting revenue outlook
Financial Impact
Q2 adjusted EPS beat consensus by $0.48 (37.4%); full-year adjusted EPS guidance raised by $0.65 at midpoint; full-year revenue growth guidance reduced by ~100bps at midpoint
Risk Factors
- Slower-than-expected Biotronik integration could lead to further revenue guidance reductions
- Activist investor campaign may create strategic uncertainty or force suboptimal capital allocation
- Execution risk on achieving ~$50M in annualized restructuring savings by mid-2028
- Potential IEEPA tariff refunds are excluded from guidance, creating uncertainty in cash flow
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 7 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0000096943-26-000091 |
| Exhibit: exhibit992to8-6x2026req2.htm | 0000096943-26-000091 |
| Document: tfx-20260806.htm | 0000096943-26-000091 |
| Document: 0000096943-26-000091-index-headers.html | 0000096943-26-000091 |
| Document: 0000096943-26-000091-index.html | 0000096943-26-000091 |
| Document: 0000096943-26-000091.txt | 0000096943-26-000091 |
| 8-K Data (Synthetic) | 0000096943-26-000091 |
Track record builds as more directional reports settle.
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Aug 6, 2026 8w ago | 8-K | $138.89 $139.96 | ▲ +0.77% | ▲ +0.17% | $124.12 (−10.63%) |
Jul 2, 2026 13w ago | Court Ruling | $133.99 $132.30 | ▼ −1.26% | ▼ −0.85% | $124.12 (−7.37%) |
Jun 22, 2026 14w ago | Institutional Cluster | $121.67 $134.61 | ▲ +10.64% | ▲ +10.78% | $124.12 (+2.01%) |
Jun 15, 2026 15w ago | 8-K | $127.87 $130.16 | ▲ +1.79% | ▲ +1.59% | $124.12 (−2.93%) |
Jun 9, 2026 16w ago | 8-K | $132.15 $134.04 | ▲ +1.43% | ▼ −2.19% | $124.12 (−6.08%) |
Jun 1, 2026 17w ago | 8-K | $127.31 $127.49 | ▲ +0.14% | ▲ +2.45% | $124.12 (−2.51%) |
May 27, 2026 18w ago | 8-K | $128.90 $127.79 | ▼ −0.86% | ▲ +1.83% | $124.12 (−3.71%) |
May 7, 2026 21w ago | 8-K | $131.59 $128.56 | ▼ −2.31% | ▼ −5.44% | $124.12 (−5.68%) |
Feb 26, 2026 31w ago | 8-K | $118.39 $110.38 | ▼ −6.77% | ▼ −0.36% | $124.12 (+4.84%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access